Full Text View
Tabular View
No Study Results Posted
Related Studies
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
This study is ongoing, but not recruiting participants.
Study NCT00134654   Information provided by Dana-Farber Cancer Institute
First Received: August 24, 2005   Last Updated: October 30, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Premarin
Additional drug interventions recognized in this trial
Androgens
Estrogens
Estrogens, Conjugated (USP)
More general drug interventions related to this trial
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Faulkner Hospital
Lowell General Hospital
South Shore Hospital
Emerson Hospital
Saint Anne's Hospital


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services